Allogene Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Allogene Therapeutics, Inc., a Delaware biotechnology company, filed a Form 8-K dated April 10, 2019. The filing reports a legal and governance matter under Item 8.01, “Other Events.” It does not provide quarterly or annual financial results.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics.
Material Change and Legal Matter
- The company’s amended and restated certificate of incorporation and bylaws, both effective October 15, 2018, contain provisions designating federal district courts as the exclusive forum for claims arising under the Securities Act of 1933, unless the company consents to another forum.
- On December 19, 2018, the Delaware Court of Chancery held in Sciabacucchi v. Salzberg that provisions of this type are invalid under Delaware law.
- In light of that decision, Allogene stated that it does not intend to enforce the federal forum provisions unless the Delaware Court of Chancery or the Delaware Supreme Court determines that such provisions are valid under Delaware law.
Outlook, Risks, and Contingencies
- If the Delaware Supreme Court ultimately determines that such provisions are invalid, the board intends to amend the bylaws to remove the provision and anticipates seeking stockholder approval to amend the certificate of incorporation accordingly.
- The filing concerns potential litigation forum selection and corporate-governance changes; it does not disclose any operating outlook, financial guidance, or unusual financial items.
Facts Investors Should Verify
- The final status of the Delaware litigation and the enforceability of federal forum provisions.
- Whether the company subsequently amended its bylaws or certificate of incorporation.
- Any related stockholder vote, litigation, or disclosure of legal expenses or contingencies in later filings.